CYTOKINETICS, INCORPORATED (CYTK) Current Ratio
- Current ratio · latest quarter: Value 6.66×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.66× | Current assets / current liabilities. $1.21B ÷ $181.43M ≈ 6.66× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.21B USD | Assets, Current |
| Current obligations | 181.43M USD | Liabilities, Current |
| Cash and equivalents | 255.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 910.41M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 24.43M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 380.00K USD | Inventory, Net |
| Payables | 20.51M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 27.36M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.21B | $181.43M | $255.27M | $910.41M | $24.43M | $380.00K | $20.51M | $27.36M | 6.66× |
| 2026-03-31 | $839.47M | $199.19M | $129.84M | $688.71M | $6.83M | $154.00K | $24.71M | $44.81M | 4.21× |
| 2025-12-31 | $916.98M | $202.45M | $122.52M | $759.70M | $17.76M | $0.00 | $22.34M | $41.18M | 4.53× |
| 2025-09-30 | $977.35M | $142.14M | $225.47M | $737.07M | $1.81M | (m) | $22.08M | $17.28M | 6.88× |
| 2025-06-30 | $886.54M | $131.06M | $74.94M | $783.20M | $8.41M | (m) | $16.23M | $14.40M | 6.76× |
| 2025-03-31 | $956.05M | $159.73M | $73.68M | $864.54M | $2.01M | (m) | $13.94M | $12.96M | 5.99× |
| 2024-12-31 | $1.11B | $179.67M | $94.86M | $981.16M | $16.65M | (m) | $20.37M | $11.52M | 6.17× |
| 2024-09-30 | $1.02B | $109.81M | $46.89M | $964.80M | $244.00K | (m) | $11.58M | $11.52M | 9.28× |
| 2024-06-30 | $1.07B | $102.78M | $190.14M | $866.63M | $0.00 | (m) | $9.47M | $11.52M | 10.39× |
| 2024-03-31 | $638.70M | $88.86M | $119.98M | $498.99M | $834.00K | (m) | $12.97M | $11.52M | 7.19× |
| 2023-12-31 | $628.05M | $102.68M | $113.02M | $501.80M | $1.28M | (m) | $21.51M | $10.08M | 6.12× |
| 2023-09-30 | $561.42M | $77.72M | $99.69M | $439.55M | $2.50M | (m) | $13.80M | (m) | 7.22× |
| 2023-06-30 | $586.58M | $65.62M | $68.64M | $497.08M | $985.00K | (m) | $12.56M | (m) | 8.94× |
| 2023-03-31 | $680.63M | $75.22M | $101.62M | $562.35M | $1.01M | (m) | $17.36M | (m) | 9.05× |
| 2022-12-31 | $795.19M | $84.62M | $65.58M | $717.00M | $147.00K | (m) | $25.61M | $958.00K | 9.40× |
| 2022-09-30 | $884.27M | $76.50M | $106.24M | $761.43M | $2.29M | (m) | $14.43M | (m) | 11.56× |
| 2022-06-30 | $602.25M | $66.84M | $93.63M | $492.39M | $1.97M | (m) | $14.08M | (m) | 9.01× |
| 2022-03-31 | $623.53M | $66.85M | $115.42M | $493.55M | $6.06M | (m) | $19.84M | (m) | 9.33× |
| 2021-12-31 | $535.67M | $71.86M | $112.67M | $358.97M | $51.82M | (m) | $21.09M | (m) | 7.45× |
| 2021-09-30 | $494.94M | $80.87M | $90.56M | $387.07M | $644.00K | (m) | $16.22M | $16.88M | 6.12× |
| 2021-06-30 | $364.23M | $61.77M | $37.15M | $313.15M | $2.70M | (m) | $14.93M | $11.25M | 5.90× |
| 2021-03-31 | $433.12M | $35.93M | $44.59M | $380.98M | $4.51M | (m) | $7.77M | $5.63M | 12.05× |
| 2020-12-31 | $474.22M | $31.20M | $82.98M | $381.07M | $4.42M | (m) | $8.05M | (m) | 15.20× |
| 2020-09-30 | $418.41M | $27.57M | $200.81M | $209.45M | $4.96M | (m) | $6.74M | (m) | 15.17× |
| 2020-06-30 | $218.95M | $22.70M | $61.13M | $151.93M | $2.25M | (m) | $2.92M | (m) | 9.65× |
| 2020-03-31 | $225.94M | $20.74M | $49.78M | $170.93M | $2.70M | (m) | $3.53M | (m) | 10.89× |
| 2019-12-31 | $233.75M | $26.02M | $36.43M | $188.68M | $5.16M | (m) | $8.16M | (m) | 8.98× |
| 2019-09-30 | $176.53M | $21.52M | $39.63M | $126.41M | $6.58M | (m) | $3.41M | $0.00 | 8.20× |
| 2019-06-30 | $184.95M | $21.96M | $34.36M | $138.51M | $8.99M | (m) | $5.19M | $0.00 | 8.42× |
| 2019-03-31 | $186.40M | $26.28M | $39.41M | $137.21M | $4.17M | (m) | $2.55M | $6.21M | 7.09× |
| 2018-12-31 | $207.67M | $22.19M | $42.26M | $156.47M | $2.23M | (m) | $3.76M | $2.61M | 9.36× |
| 2018-09-30 | $227.27M | $21.49M | $27.62M | $182.69M | $9.16M | (m) | $2.02M | $3.78M | 10.57× |
| 2018-06-30 | $244.23M | $27.29M | $46.95M | $184.99M | $236.00K | (m) | $1.34M | $1.70M | 8.95× |
| 2018-03-31 | $272.34M | $38.55M | $115.01M | $136.44M | $37.00K | (m) | $2.42M | $0.00 | 7.07× |
| 2017-12-31 | $274.30M | $32.44M | $125.21M | $143.69M | $1.11M | (m) | $5.25M | $0.00 | 8.45× |
| 2017-09-30 | $321.99M | $42.36M | $116.32M | $191.25M | $10.00M | (m) | $4.08M | $9.83M | 7.60× |
| 2017-06-30 | $317.00M | $31.06M | $100.71M | $211.34M | (m) | (m) | $1.78M | $7.32M | 10.21× |
| 2017-03-31 | $211.02M | $36.80M | $49.36M | $157.19M | (m) | (m) | $3.04M | $4.83M | 5.73× |
| 2016-12-31 | $158.63M | $33.26M | $66.87M | $89.38M | $24.00K | (m) | $4.24M | $2.50M | 4.77× |
| 2016-09-30 | $148.18M | $27.86M | $30.30M | $48.31M | (m) | (m) | $668.00K | (m) | 5.32× |
| 2016-06-30 | $96.62M | $26.27M | $27.72M | $62.61M | (m) | (m) | $2.85M | (m) | 3.68× |
| 2016-03-31 | $106.12M | $24.68M | $42.27M | $61.15M | (m) | (m) | $547.00K | (m) | 4.30× |
| 2015-12-31 | $113.11M | $31.65M | $65.08M | $46.37M | (m) | (m) | $2.24M | $0.00 | 3.57× |
| 2015-09-30 | $100.52M | $30.14M | $25.96M | $72.02M | (m) | (m) | $1.91M | (m) | 3.33× |
| 2015-06-30 | $107.90M | $29.11M | $24.84M | $80.34M | (m) | (m) | $1.60M | (m) | 3.71× |
| 2015-03-31 | $110.81M | $25.39M | $22.55M | $85.32M | (m) | (m) | $1.39M | (m) | 4.37× |
| 2014-12-31 | $131.13M | $23.86M | $20.21M | $63.01M | (m) | (m) | $1.36M | (m) | 5.50× |
| 2014-09-30 | $81.49M | $12.99M | $12.91M | $65.59M | (m) | (m) | $1.65M | (m) | 6.28× |
| 2014-06-30 | $80.08M | $16.92M | $12.36M | $65.39M | (m) | (m) | $985.00K | (m) | 4.73× |
| 2014-03-31 | $86.05M | $19.79M | $13.26M | $69.09M | (m) | (m) | $1.69M | (m) | 4.35× |
| 2013-12-31 | $79.34M | $26.70M | $20.16M | $57.57M | (m) | (m) | $3.71M | (m) | 2.97× |
| 2013-09-30 | $83.32M | $45.01M | $19.26M | $62.38M | (m) | (m) | $1.79M | (m) | 1.85× |
| 2013-06-30 | $93.62M | $34.05M | $17.06M | $58.60M | (m) | (m) | $1.80M | (m) | 2.75× |
| 2013-03-31 | $63.66M | $5.82M | $13.16M | $48.44M | (m) | (m) | $1.09M | (m) | 10.94× |
| 2012-12-31 | $76.43M | $7.11M | $14.91M | $59.09M | (m) | (m) | $2.00M | (m) | 10.76× |
| 2012-09-30 | $78.77M | $4.59M | $15.39M | $60.22M | (m) | (m) | $1.52M | (m) | 17.16× |
| 2012-06-30 | $92.96M | $3.99M | $63.65M | $26.82M | (m) | (m) | $1.05M | (m) | 23.30× |
| 2012-03-31 | $45.22M | $4.47M | $17.82M | $25.27M | (m) | (m) | $926.00K | (m) | 10.12× |
| 2011-12-31 | $51.14M | $4.59M | $18.83M | $30.19M | (m) | (m) | $1.20M | (m) | 11.14× |
| 2011-09-30 | $59.87M | $5.03M | $18.59M | $38.99M | (m) | (m) | $1.45M | (m) | 11.89× |
| 2011-06-30 | $69.80M | $5.50M | $23.77M | $43.14M | (m) | (m) | $1.00M | (m) | 12.68× |
| 2010-12-31 | $73.50M | $7.32M | $17.51M | $54.13M | (m) | (m) | $1.12M | (m) | 10.04× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |